Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
GridAI Technologies Corp. (GRDX) operates in the ELECTRIC & OTHER SERVICES COMBINED sector and is listed on NASDAQ. The stock is currently priced at $2.99, with a market capitalisation of $21.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.87 to $6.93. This page covers its latest market performance, valuation, price trends and company information.
$21.18M | |
$2.89 | |
$6.93 | |
$1.87 | |
$2.97 | |
61.85K | |
99.41K | |
-- | |
$6.93 | |
$1.87 | |
-- | |
-- |
GridAI Technologies Corp. (GRDX) is trading at $3.05 in pre-market trading as of 2026-09-15 20:11:00, up 2.53% ($0.07) from the previous close of $2.97
Pre-market trading shows how investors are pricing GRDX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, GridAI Technologies Corp. (GRDX) moved from $3.25 to $2.99, representing a decline of 8.00% ($0.26).
The stock traded between $2.75 and $3.46 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 91.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.1%
GRDX is currently trading at $2.99, placing it 22.1% of the way from its 52-week low of $1.87 to its 52-week high of $6.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
| Industry | ELECTRIC & OTHER SERVICES COMBINED |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GridAI Technologies Corp. (GRDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.